Benzinga | Jun 21, 2021 06:16AM EDT

Barclays Downgrades Arcturus Therapeutics to Underweight, Lowers Price Target to $25

Barclays analyst Gena Wang downgrades Arcturus Therapeutics (NASDAQ:ARCT) from Equal-Weight to Underweight and lowers the price target from $33 to $25.